Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083967 · ClinicalTrials.gov registry record · Phase 2
Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment
A Phase 2 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00083967 is a Phase 2 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 23 participants.
The verdict
NCT00083967, a Phase 2 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to test if denufosol will remove the fluid build-up in the eye so that the retina can be re-attached without invasive surgery.
Interventions
- DRUG denufosol tetrasodium (INS37217) Intravitreal Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2004-06 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00083967
The ClinicalTrials.gov registry entry for NCT00083967 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which denufosol tetrasodium (INS37217) Intravitreal Injection is the first listed.
NCT00083967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00083967 about?
NCT00083967 is a clinical study titled "Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment". The purpose of this study is to test if denufosol will remove the fluid build-up in the eye so that the retina can be re-attached without invasive surgery.
What is the current status of trial NCT00083967?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2004-06. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00083967?
The interventions under investigation include: denufosol tetrasodium (INS37217) Intravitreal Injection (DRUG).
Who is sponsoring clinical trial NCT00083967?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.